1-10 of 10
Oleg Zernovak
Close
Sort by
Journal Articles

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Gail J. Roboz, Marina Konopleva, Hongtao Liu, Gary J. Schiller, Elias J. Jabbour, Deborah Whitfield, Asifa Haider, Oleg Zernovak, Mark G. Frattini, Carrie Brownstein, Richard A. Larson
Journal: Blood
Blood (2021) 138 (Supplement 1): 1746.
https://doi.org/10.1182/blood-2021-150779
Published: 2021
Journal Articles

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, MD, Gail J. Roboz, MD, Marina Konopleva, MD PhD, Hongtao Liu, MD PhD, Elias Jabbour, MD, Camille Poirot, Pharm.D., Cécile Schiffer-Manniou, PhD, Agnès Gouble, PhD, Asifa Haider, PhD, Oleg Zernovak, MD, Richard A. Larson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-138594
Published: 2020
Journal Articles

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

Michael Andreeff, MD PhD, Weiguo Zhang, MD PhD, Prasanna Kumar, PhD, Oleg Zernovak, MD, Naval G. Daver, MD, Takeshi Isoyama, PhD, Kouichi Iwanaga, D.V.M, PhD, Noriko Togashi, Takahiko Seki, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2720.
https://doi.org/10.1182/blood-2018-99-115183
Published: 2018
Journal Articles

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

Courtney D DiNardo, MD, Joseph Rosenthal, MD MS, Michael Andreeff, MD PhD, Oleg Zernovak, MD, Prasanna Kumar, PhD, Roohi Gajee, PhD, Shuquan Chen, PhD, Michael Rosen, PhD, Saeheum Song, PhD, Jarema Kochan, PhD, Tharin Limsakun, PhD, Rebecca Olin, MD
Journal: Blood
Blood (2016) 128 (22): 593.
https://doi.org/10.1182/blood.V128.22.593.593
Published: 2016
Journal Articles

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Jorge E. Cortes, MD, Ricardo Pasquini, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Zhixiang Shen, MD, Carmen Piccolo, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, Dawn F. Eng, Dong-Wook Kim, Timothy P. Hughes, MD, MBBS
Journal: Blood
Blood (2012) 120 (21): 3750.
https://doi.org/10.1182/blood.V120.21.3750.3750
Published: 2012
Journal Articles

Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.

Robert Hermann, MD FACP, Carole B. Miller, MD, Rosalind Catchatorian, MD, David S. Snyder, MD, Solveig G. Ericson, MD, PhD, Oleg Zernovak, MD, Matthews A Juma, Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 2781.
https://doi.org/10.1182/blood.V120.21.2781.2781
Published: 2012
Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman
Journal: Blood
Blood (2012) 120 (21): 4439.
https://doi.org/10.1182/blood.V120.21.4439.4439
Published: 2012
Journal Articles

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Ricardo Pasquini, MD, Jorge E. Cortes, Hagop M. Kantarjian, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, LaTonya Collins, BSN, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 1695.
https://doi.org/10.1182/blood.V118.21.1695.1695
Published: 2011
Journal Articles

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

François Guilhot, MD, John Coombs, PharmD, MBA, Oleg Zernovak, MD, Tomasz Szczudlo, Gianantonio Rosti
Journal: Blood
Blood (2010) 116 (21): 1514.
https://doi.org/10.1182/blood.V116.21.1514.1514
Published: 2010
Journal Articles

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

François Guilhot, MD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Oleg Zernovak, MD, Nancy J. Macdonald, PhD, Ari Shapiro, PhD
Journal: Blood
Blood (2010) 116 (21): 394.
https://doi.org/10.1182/blood.V116.21.394.394
Published: 2010